Achaogen hits, then misses: FDA OKs Zemdri for cUTIs, but rejects second indication
Following an advisory committee’s suggestions back in May, the FDA has handed one approval — and one rejection — to Achaogen’s lead antibiotic.
Although somewhat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
